乙酰半胱氨酸联合沙美特罗替卡松治疗慢性阻塞性肺疾病的疗效分析

The effect of N-acetylcysteine combined with Shah Mette Lo Tikason in the treatment of chronic obstructive pulmonary disease

目的 探讨乙酰半胱氨酸联合沙美特罗替卡松治疗慢性阻塞性肺疾病的疗效分析.方法 采用单中心前瞻对照研究,将收治的慢性阻塞性肺疾病（COPD）稳定期59 例患者,随机分为试验组与对照组,对照组采用常规治疗方法予常规祛痰、平喘治疗.试验组采用乙酰半胱氨酸联合沙美特罗替卡松粉吸入剂治疗.两组患者均随访1 ～ 1.5 年,观察两组患者肺功能、步行6 min 距离、呼吸困难评分、诱导痰细胞计数.结果 两组治疗前后,以及两组治疗后比较,试验组肺功能评分FEV1、FEV1%,步行6 min 距离、呼吸困难评分优于对照组,差异有统计学意义（P 〈 0.05）;从诱导痰细胞分类计数的变化可以看出,在中性粒细胞数计数、中性粒细胞占细胞总数百分比、单核细胞占细胞总数百分比等方面,试验组均优于对照组,差异均具有统计学意义（P 〈 0.05）.结论 乙酰半胱氨酸联合沙美特罗替卡松治疗慢性阻塞性肺疾病效果显著.

Objective To investigate the effect of N-acetylcysteine combined with Shah Mette Lo Tikason in the treatment of chronic obstructivepulmonary disease branch. Methods A prospective control study of single center, from January 2010 in our affiliated hospital, the patients with chronicobstructive pulmonary disease（ COPD） in stable were randomly divided into experimental group and control group. The control group was with conventionaltreatment with conventional expectorant. And the experimental group was treated with N-acetylcysteine combined with salmeterol and fluticasone propionatepowder for inhalation therapy. Two groups of patients were followed up to observe patients’ pulmonary function, walking 6 min walking distance, dyspnea scorecomparison, induced sputum cell counts in 1 to 1.5 years. Results After treatment, the pulmonary function score of FEV1/FEV1%, 6 min walking distanceand breathing difficulties in experimental group were significantly better than those in the control group（P 〈 0.05）. The neutrophil count, Neutrophilspercentage of cells, monocytes constitute the total cell percentage of experimental group were much better than those of the control group（ P 〈 0.05）.Conclusion N-acetylcysteine combined with Shah Mette Lo Tikason has a significant therapeutic effect on chronic obstructive pulmonary disease.